APA (7th ed.) Citation

Voskoboynik, M., Mileshkin, L., Gan, H., Millward, M., Au-Yeung, G., Meniawy, T., . . . Lickliter, J. (2019). 452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results. Annals of Oncology, 30, v167. https://doi.org/10.1093/annonc/mdz244.014

Chicago Style (17th ed.) Citation

Voskoboynik, M., et al. "452PD - Safety, Antitumor Activity, and Pharmacokinetics (PK) of Pamiparib (BGB-290), a PARP1/2 Inhibitor, in Patients (pts) with Advanced Solid Tumours: Updated Phase I Dose-escalation/expansion Results." Annals of Oncology 30 (2019): v167. https://doi.org/10.1093/annonc/mdz244.014.

MLA (9th ed.) Citation

Voskoboynik, M., et al. "452PD - Safety, Antitumor Activity, and Pharmacokinetics (PK) of Pamiparib (BGB-290), a PARP1/2 Inhibitor, in Patients (pts) with Advanced Solid Tumours: Updated Phase I Dose-escalation/expansion Results." Annals of Oncology, vol. 30, 2019, p. v167, https://doi.org/10.1093/annonc/mdz244.014.